Phycocyanin's commercial story is broadening from colorant to studied bioactive. A growing body of research examines its antioxidant and anti-inflammatory activity, drawing interest from nutraceutical and pharmaceutical developers, while the diagnostics field values its fluorescent properties.
Two demand engines
- Diagnostics and life science: steady demand for natural fluorescent proteins as labels and reagents, where high purity commands a premium.
- Bioactive research: ongoing investigation of phycocyanin's biological properties, which, while still maturing, sustains interest from formulators positioning premium products.
A measured view of the science
It is important to distinguish documented applications (fluorescent labeling, colorant) from areas still under research (therapeutic bioactivity). Responsible positioning presents the latter as promising and investigational rather than established, which also builds credibility with sophisticated buyers.
Market direction
The high-purity phycocyanin segment is smaller in volume but higher in value than food-grade, and it rewards suppliers who can guarantee consistency and documentation. As diagnostics and research budgets grow, this segment is positioned to expand.
The planning implication
Buyers serving these segments benefit from early alignment on grade, specification, and documentation ahead of the 2027 window.
Forward-looking note: SPIRUVA is in a pre-launch phase, with commercial production scheduled for July 2027. Bioactive properties referenced are investigational; market figures are directional, not guarantees.
◦ Premium Download
Get the typeset PDF report.
Branded, beautifully formatted, sharable with your procurement, R&D, and formulation teams.
About the Author
Spiruva Research Team
Industry Intelligence Desk
Spiruva's editorial team includes co-founders and industry researchers covering the global phycocyanin and spirulina markets. We publish data-driven articles that help B2B buyers make better procurement decisions.